scholarly journals Efficacy of Brompheniramine Maleate for the Treatment of Rhinovirus Colds

1997 ◽  
Vol 25 (5) ◽  
pp. 1188-1194 ◽  
Author(s):  
Jack M. Gwaltney, Jr. ◽  
Howard M. Druce
Keyword(s):  
Brompheniramine Maleate

Brompheniramine Maleate: A Double-Blind, Placebo-Controlled Comparison with Terfenadine for Symptoms of Allergic Rhinitis

1998 ◽  
Vol 12 (4) ◽  
pp. 293-300 ◽  
Author(s):  
William R. Thoden ◽  
Howard M. Druce ◽  
Sandy A. Furey ◽  
Earle A. Lockhart ◽  
Paul Ratner ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Severity ◽  
Extended Release ◽  
Nasal Symptom ◽  
Double Blind ◽  
Release Formulation ◽  
Extended Release Formulation ◽  
Adverse Experiences ◽  
Severity Scores ◽  
Brompheniramine Maleate

This was a double-blind, randomized, placebo-controlled, multicenter, parallel study comparing the effectiveness, at recommended doses, of an extended-release formulation of brompheniramine maleate and terfenadine in the treatment of allergic rhinitis. Subjects with symptoms of seasonal and/or perennial allergic rhinitis received brompheniramine 12 mg (n = 106), 8 mg (n = 105), terfenadine 60 mg (n = 106), or placebo (n = 53) twice daily for 14 days. On treatment days 3, 7, and 14, symptom severity ratings (i.e., rhinorrhea, sneezing, nasal congestion, itchy nose, eyes or throat, excessive tearing, postnasal drip) were completed by the physician; subjects and physicians each completed a global efficacy evaluation. Brompheniramine 12 mg and 8 mg and terfenadine were more effective than placebo (p ≤ 0.05) on the physicians’ global; brompheniramine 12 mg was more effective than terfenadine (p ≤ 0.05) on days 7 and 14 and brompheniramine 8 mg on day 3. On the subjects’ global evaluation, brompheniramine 12 mg and 8 mg and terfenadine were more effective than placebo (p ≤ 0.05); brompheniramine 12 mg was more effective than terfenadine (p ≤ 0.05) on days 7 and 14 and brompheniramine 8 mg on day 3. In general, brompheniramine 8 mg was comparable to terfenadine. On days 3 and 7, the total symptom and total nasal symptom severity scores for subjects receiving brompheniramine 12 mg were significantly more improved than for placebo (p < 0.05); terfenadine was not different from placebo; brompheniramine 12 mg was significantly better than terfenadine on day 7 (p < 0.05) for reducing total symptom severity and on days 3, 7, and 14 for reducing total nasal symptom severity. Adverse experiences were reported by 155 (41.9%) of the 370 subjects enrolled in the study. The overall rate of adverse experiences in the brompheniramine 12 mg treatment group (57.5%) was significantly greater (p < 0.05) than for brompheniramine 8 mg (38.1%), terfenadine (31.1%), and placebo (39.6%). In conclusion, an extended-release formulation of brompheniramine 12 mg or 8 mg bid alleviates allergic rhinitis symptoms and brompheniramine 12 mg provides significantly better relief of these symptoms than terfenadine 60 mg bid.

Semiautomated Method for the Analysis of Formulations of Chlorpheniramine Maleate and Brompheniramine Maleate

1979 ◽  
Vol 62 (3) ◽  
pp. 552-555
Author(s):  
Don C Cox ◽  
Ross D Kirchhoefer
Keyword(s):  
Acid Solution ◽  
Active Ingredient ◽  
Dilute Acid ◽  
Chlorpheniramine Maleate ◽  
Precision Data ◽  
Dilute Acid Solution ◽  
Aqueous Layer ◽  
Brompheniramine Maleate ◽  
Semiautomated Method

Abstract The determination of chlorpheniramine maleate and brompheniramine maleate in tablets, capsules, injections, and elixirs has been automated. The active ingredient is dissolved in dilute HCl. The dilute acid solution is sampled, made basic with dilute NaOH, and extracted with isooctane. The isooctane phase is resampled and the drug is re-extracted into dilute HCl. The absorbance of the acidic aqueous layer is monitored at 265 nm. The method is an automated version of the general USP XIX assay for salts of organic nitrogenous bases. The results from the semiautomated procedure agree well with the USP XIX and NF XIV official methods. Recoveries were 100% from an authentic tablet material. The system is linear from 0 to 300% of declared potency. The procedure is free from common excipient and dye interferences. Precision data are included for both the automated and official methods.

Withdrawal symptoms after discontinuation of long-acting brompheniramine maleate

1994 ◽  
Vol 131 (6) ◽  
pp. 913-914 ◽  
Author(s):  
G.M. Kavanagh ◽  
M.R. Charlwood ◽  
R.D. Peachey
Keyword(s):  
Withdrawal Symptoms ◽  
Long Acting ◽  
Brompheniramine Maleate

Terfenadine and Brompheniramine Maleate in Urticaria and Dermographism

Dermatology ◽  
1986 ◽  
Vol 173 (1) ◽  
pp. 5-8 ◽  
Author(s):  
Anthony D. Ormerod ◽  
Roger Baker ◽  
Jane Watt ◽  
Marion I. White
Keyword(s):  
Brompheniramine Maleate

X-Ray Powder Diffraction Data for Selected Drugs: Furosemide, Hydrochlorothiazide, Naproxen, Naproxen Sodium, Propranolol Hydrochloride, and the Halopheniramine Maleates

1984 ◽  
Vol 67 (5) ◽  
pp. 927-933 ◽  
Author(s):  
Wilson H De Camp
Keyword(s):  
Powder Diffraction ◽  
Diffraction Data ◽  
Naproxen Sodium ◽  
Crystal Structure Data ◽  
Propranolol Hydrochloride ◽  
Powder Diffraction Data ◽  
X Ray ◽  
Drug Substances ◽  
Racemic Mixtures ◽  
Brompheniramine Maleate

Abstract X-ray powder diffraction data for 9 commonly used drug substances are reported. The data for furosemide, hydrochlorothiazide, propranolol hydrochloride, dexchlorpheniramine maleate, and brompheniramine maleate have been indexed by reference to published crystal structure data. The racemic modifications of propranolol hydrochloride and brompheniramine maleate are shown to exist as racemic compounds rather than racemic mixtures.

Sign in / Sign up

Export Citation Format

Share Document